JP2020514286A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514286A5
JP2020514286A5 JP2019535891A JP2019535891A JP2020514286A5 JP 2020514286 A5 JP2020514286 A5 JP 2020514286A5 JP 2019535891 A JP2019535891 A JP 2019535891A JP 2019535891 A JP2019535891 A JP 2019535891A JP 2020514286 A5 JP2020514286 A5 JP 2020514286A5
Authority
JP
Japan
Prior art keywords
raav
promoter
suspension
enhancer
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019535891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514286A (ja
JP7128190B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/068919 external-priority patent/WO2018126116A1/en
Publication of JP2020514286A publication Critical patent/JP2020514286A/ja
Publication of JP2020514286A5 publication Critical patent/JP2020514286A5/ja
Application granted granted Critical
Publication of JP7128190B2 publication Critical patent/JP7128190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019535891A 2016-12-30 2017-12-29 ウィルソン病を処置するための遺伝子療法 Active JP7128190B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662440659P 2016-12-30 2016-12-30
US62/440,659 2016-12-30
US201762473656P 2017-03-20 2017-03-20
US62/473,656 2017-03-20
PCT/US2017/068919 WO2018126116A1 (en) 2016-12-30 2017-12-29 Gene therapy for treating wilson's disease

Publications (3)

Publication Number Publication Date
JP2020514286A JP2020514286A (ja) 2020-05-21
JP2020514286A5 true JP2020514286A5 (https=) 2021-01-28
JP7128190B2 JP7128190B2 (ja) 2022-08-30

Family

ID=62710046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535891A Active JP7128190B2 (ja) 2016-12-30 2017-12-29 ウィルソン病を処置するための遺伝子療法

Country Status (9)

Country Link
US (2) US11473106B2 (https=)
EP (2) EP3562514B1 (https=)
JP (1) JP7128190B2 (https=)
KR (2) KR102863181B1 (https=)
CN (1) CN110290814A (https=)
BR (1) BR112019013245A2 (https=)
CA (1) CA3048044A1 (https=)
MX (1) MX2019007873A (https=)
WO (1) WO2018126116A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007873A (es) 2016-12-30 2019-11-18 Univ Pennsylvania Terapia génica para tratar la enfermedad de wilson.
IL274926B2 (en) 2017-12-01 2026-04-01 Encoded Therapeutics Inc Pyrazolopyrimidines with activity against respiratory syncytial virus
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
CN111902164A (zh) 2018-02-01 2020-11-06 同源药物公司 用于恢复pah基因功能的腺相关病毒组合物及其使用方法
CN112041437A (zh) 2018-02-19 2020-12-04 同源药物公司 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
EP3861131A4 (en) * 2018-10-01 2022-06-15 Ultragenyx Pharmaceutical Inc. GENE THERAPY FOR THE TREATMENT OF PROPIONIC ACIDosis
TW202039854A (zh) * 2018-11-16 2020-11-01 美商編碼製藥公司 治療威爾遜氏病的組合物和方法
KR20210112339A (ko) 2019-01-04 2021-09-14 울트라제닉스 파마수티컬 인코포레이티드 윌슨병을 치료하기 위한 유전자 요법 구축물
WO2020243651A1 (en) 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
CN111088285B (zh) * 2019-08-15 2021-12-28 北京锦篮基因科技有限公司 携带atp7b基因表达框及变异体的aav载体及应用
EP4067495A4 (en) * 2019-11-26 2023-06-14 Korea Research Institute of Bioscience and Biotechnology MRNA CONSTRUCT FOR PROTEIN EXPRESSION AND ITS USE
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復pah基因功能的腺相關病毒組成物及其使用方法
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022208342A1 (en) * 2021-04-01 2022-10-06 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
CN115216481A (zh) * 2021-04-21 2022-10-21 四川至善唯新生物科技有限公司 一种表达量提高的截短型atp7b基因及其应用
US20250144239A1 (en) * 2021-10-18 2025-05-08 Logicbio Therapeutics, Inc. Gene therapy for the treatment of wilson's disease
WO2023230466A1 (en) * 2022-05-23 2023-11-30 Lutsenka Svetlana Compositions and methods for treating wilson's disease
CN115216533A (zh) * 2022-06-30 2022-10-21 湖南家辉生物技术有限公司 一种用于诊断威尔逊病的生物标志物、扩增引物组、检测试剂及应用
WO2024183769A1 (en) * 2023-03-06 2024-09-12 Lingyi Biotech Co., Ltd. A truncated atp7b and the use thereof
JP2026508707A (ja) * 2023-03-22 2026-03-11 スカイライン、セラピューティクス、リミテッド ウィルソン病の遺伝子療法のための組換えaav
US20240360431A1 (en) * 2023-04-30 2024-10-31 Sichuan Real&Best Biotech Co., Ltd. Engineered alpha-galactosidase a (a-gal a) peptides and functional variants thereof and associated methods of treating fabry disease
WO2025026198A1 (en) * 2023-07-28 2025-02-06 Lingyi Biotech Co., Ltd. Polynucleotides for the treatment of wilson disease
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease
CN117947035A (zh) * 2024-03-25 2024-04-30 上海凌医生物科技有限公司 一种增强基因表达的启动子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985553B2 (en) 2001-10-29 2011-07-26 Nathaniel Heintz Method for isolating cell type-specific mRNAs
DE10156121A1 (de) 2001-11-16 2003-05-28 Wolfgang Stremmel Somatische Gentherapie mit Vektoren, die einen verkürzten metallsensitiven Promotor besitzen, zur Behandlung des Morbus Wilson sowie anderer Erkrankungen, die mit Veränderungen im Metallstoffwechsel einhergehen, wie z.B. Alzheimer-Erkrankung
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP1660970A4 (en) 2003-08-01 2007-02-14 Dna Twopointo Inc SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US20150045284A1 (en) 2011-01-21 2015-02-12 Aarhus Universitet CRYSTAL STRUCTURE OF A TYPE IB P-TYPE ATPase
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
AU2013221212B2 (en) 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
EP3233129B1 (en) 2014-12-17 2020-01-15 Fundacion para la Investigacion Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
ES2876412T3 (es) 2014-12-17 2021-11-12 Fundacion Para La Investig Medica Aplicada Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
WO2017100676A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
MX2019007873A (es) 2016-12-30 2019-11-18 Univ Pennsylvania Terapia génica para tratar la enfermedad de wilson.
TW202039854A (zh) * 2018-11-16 2020-11-01 美商編碼製藥公司 治療威爾遜氏病的組合物和方法
KR20210112339A (ko) 2019-01-04 2021-09-14 울트라제닉스 파마수티컬 인코포레이티드 윌슨병을 치료하기 위한 유전자 요법 구축물

Similar Documents

Publication Publication Date Title
JP2020514286A5 (https=)
JP2019513794A5 (https=)
RU2018136611A (ru) Генная терапия для лечения гемофилии a
JP7374119B2 (ja) 減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型
JP2017512466A5 (https=)
JP2020510428A5 (https=)
JP2018537984A5 (https=)
JP2020519292A5 (https=)
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
US10413598B2 (en) Factor IX gene therapy
ES2640586T3 (es) Secuencias del factor VIII
JP2018531609A5 (https=)
JP2016512683A5 (https=)
JP2022500066A5 (https=)
JP2014512171A5 (https=)
JP2019513393A5 (https=)
JP2018520997A5 (https=)
JP2019513779A5 (https=)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2019503649A5 (https=)
JP2018522529A5 (https=)
TW201706412A (zh) Fabry氏病基因療法
RU2015144234A (ru) Композиции и способы лечения mps1
JP2018506261A5 (https=)
JP2019523648A5 (https=)